CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for CASI Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 34 | 43 | 30 | 15 | 4 |
Cost Of Goods | 14 | 16 | 13 | 10 | 4 |
Gross Profit | 20 | 27 | 18 | 6 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 61 | 59 | 57 | 47 |
Income After Depreciation & Amortization | -25 | -34 | -42 | -52 | -47 |
Non-Operating Income | -1 | -3 | 6 | 4 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -26 | -37 | -36 | -48 | -45 |
Income Taxes | 0 | 2 | 0 | 0 | 0 |
Minority Interest | 1 | 1 | 1 | 1 | 1 |
Investment Gains/Losses | 0 | -1 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -26 | -40 | -36 | -48 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -27 | -41 | -37 | -48 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -32 | -40 | -50 | -45 |
Depreciation & Amortization (Cash Flow) | 4 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -25 | -34 | -42 | -52 | -47 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 13.36 | 13.65 | 13.61 | 11.05 | 9.60 |
Diluted EPS Before Non-Recurring Items | -1.86 | -3.01 | -2.60 | -4.30 | -4.20 |
Diluted Net EPS (GAAP) | -2.02 | -3.01 | -2.70 | -4.40 | -4.80 |
Fiscal Year end for CASI Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.98 | 3.41 | 6.03 | 8.84 | 9.82 |
Cost Of Goods | 1.91 | 1.60 | 2.82 | 3.65 | 3.99 |
Gross Profit | 2.07 | 1.81 | 4.06 | 5.19 | 5.83 |
SG&A, R&D, and Dept/Amort Expenses | 10.85 | 11.26 | 7.48 | 10.29 | 15.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.78 | -9.45 | -3.42 | -5.10 | -9.35 |
Non-Operating Income | 1.88 | -0.01 | -2.55 | 0.64 | -0.71 |
Interest Expense | 0.06 | 0.06 | 0.00 | NA | NA |
Pretax Income | -6.97 | -9.53 | -5.97 | -4.45 | -10.06 |
Income Taxes | 0.00 | 0.00 | -0.08 | NA | NA |
Minority Interest | 0.00 | 0.00 | 0.16 | 0.17 | 0.17 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | -0.02 | -0.02 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | NA | NA |
Income From Cont. Operations | -6.97 | -9.53 | -5.48 | -4.47 | -10.24 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -6.97 | -9.53 | -5.48 | -4.64 | -10.24 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 13.52 | 13.38 | 12.28 | 13.38 | 13.35 |
Diluted EPS Before Non-Recurring Items | -0.52 | -0.71 | -0.29 | -0.35 | -0.77 |
Diluted Net EPS (GAAP) | -0.52 | -0.71 | -0.45 | -0.35 | -0.77 |